Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer
Parallel applications based on TROPION-Lung01 and TROPION-Breast01 phase 3 trial results demonstrating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan significantly improved...




















